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Background
Cisplatin and its derivatives are important drugs in cancer
therapy. It has been widely used for its potent cytotoxic
effects upon a variety of tumors types including cervical
carcinoma. However, the administration of cisplatin is
associated with serious side effects, including nephrotoxic
and neurotoxic events. There have been several studies
aimed at finding drugs able to potentiate the antiprolifer-
ative effects of cisplatin without increasing the already
serious side effects, but the search has not been successful.
In this work we investigated the ability of a progesterone
antagonist, mifepristone, to modulate the cytotoxic effects
of cisplatin in cancer cell lines and in a model of cervix
cancer in athymic mice.
Materials and methods
The effect of cisplatin alone and cisplatin combined with
mifepristone on cellular death was studied using an assay
based on a tetrazolium dye, XTT. Before and after treat-
ment with mifepristone, the intracellular accumulation of
cisplatin in cancer cells and tumors of mice receiving treat-
ment was evaluated by HPLC, the expression of Bcl-2 gene
was assessed by RT-PCR and western blotting. Tumors
measurements were performed weekly using vernier cali-
pers.
Results
Analysis of the data by the isobologram method shows
that the combination of mifepristone and cisplatin pro-
duced a synergistic effect in cervical cancer cells. The effect
of mifepristone on the cytotoxicity of cisplatin could be
mediated, at least partially, by increase of intracellular cis-
platin accumulation and the down-regulation of the Bcl-2
expression. The in vivo studies showed that the combina-
tion of these agents had a significant antitumor activity
against xenograft tumors.
Conclusion
Our results suggest that mifepristone can improve the effi-
cacy of cisplatin in cancer cells and this anti-hormonal
drug therapy may be a candidate for further evaluation in
combination with antineoplastic drugs in the treatment of
cancer.
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